Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • Subscribe to Print Magazine
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for Pixuvri®

November 1, 2010 By Bio-Medicine.Org

SEATTLE, Nov. 1, 2010 /PRNewswire/ — Cell Therapeutics, Inc.
(“CTI”) (Nasdaq and MTA: CTIC) announced today that it has
submitted a Marketing Authorization Application (“MAA”) to the
European Medicines Agency (“EMA”) for Pixuvri® (pixantrone
dimaleate) as monotherapy for the treatment of adult patients with
multiply relapsed or refractory aggressive non-Hodgkin’s lymphoma
(“NHL”). The application submission follows a positive opinion from
the EMA’s Pediatric Committee (the “PDCO”), where PDCO agreed to
CTI’s Pediatric Investigation Plan (“PIP”) for Pixuvri.

“This is an important milestone for CTI, and underscores our
commitment to making pixantrone available to patients who currently
have no approved or effective therapies for this life threatening
disease,” said James A. Bianco, M.D., CEO of CTI. “We appreciate
the efforts of all the people who made the MAA submission possible,
especially the investigators and patients who participated in our
clinical trial.”  

“PIX301 was not only the first and only randomized trial in this
patient population, it was also the largest study ever conducted
for patients with multiply relapsed and refractory aggressive NHL.
The positive results of this trial are among the most effective
ever reported in this group of patients,” noted Ruth Pettengell,
M.D., of St. George’s Hospital, University of London, the principal
investigator on the study. “The robustness of the drug’s effect in
prolonging progression free survival irrespective of risk factors
lends to the strength and credibility of the clinical benefit
provided to patients in the trial. Currently there are no approved
drugs available to patients today as such pixantrone will be a
valuable new addition to offer these patients a new hope for
controlling their disease.”

Pixantrone was granted orphan drug status by the EMA for the
treatment of diffuse large B-cell lymphoma (DLBCL). CTI expects
that the EMA will make a determination regarding the ac

‘/>”/>

SOURCE

Related Articles Read More >

TE Connectivity opens global medical device prototyping center in Ireland
Prix Galien USA 2022 nominees
The 24 best medical device innovations of 2022
A portrait of Ellen Roche, MIT School of Engineering associate professor
New implant design prevents scar tissue without drugs, MIT says
UMN artificial blood vessel clinical trial
Minnesota researchers awarded $3.7M grant for artificial, bioengineered blood vessel clinical trial

DeviceTalks Weekly.

August 12, 2022
DTW – Medtronic’s Mauri brings years of patient care to top clinical, regulatory, scientific post
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech100 Index
  • Medical Tubing + Extrusion
  • Medical Design Sourcing
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • Subscribe to Print Magazine
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech